Zevra Therapeutics Files Proxy Materials
Ticker: ZVRA · Form: DEFA14A · Filed: May 8, 2025 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | DEFA14A |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, proxy-statement
Related Tickers: ZEVRA
TL;DR
Zevra (ZEVRA) filed proxy docs, no fee. Standard stuff.
AI Summary
Zevra Therapeutics, Inc. (formerly KemPharm, Inc.) filed a Definitive Additional Materials (DEFA14A) on May 8, 2025. This filing relates to the company's proxy statement and indicates no fee was required for this filing. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing is a routine regulatory submission for Zevra Therapeutics, providing shareholders with information related to upcoming corporate decisions or meetings.
Risk Assessment
Risk Level: low — This filing is a routine DEFA14A, indicating standard corporate disclosure rather than a significant event.
Key Players & Entities
- ZEVRA THERAPEUTICS, INC. (company) — Registrant
- KEMPHARM, INC (company) — Former company name
- 0001193125-25-115961 (filing_id) — Accession Number
- 20250508 (date) — Filing Date
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing, also known as Definitive Additional Materials, is used to provide additional information to shareholders related to a proxy statement, often after the initial filing.
What was Zevra Therapeutics' former name?
Zevra Therapeutics, Inc. was formerly known as KEMPHARM, INC.
When was this filing submitted?
This filing was submitted on May 8, 2025.
Was there a filing fee associated with this document?
According to the filing, no fee was required for this submission.
What is Zevra Therapeutics' fiscal year end?
Zevra Therapeutics, Inc.'s fiscal year ends on December 31.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 8, 2025 regarding ZEVRA THERAPEUTICS, INC. (ZVRA).